Skip to main content
. 2018 Dec 24;14:195–204. doi: 10.2147/IJN.S186556

Figure 5.

Figure 5

In vivo antitumor activity of NPPA-PTX@PEG NPs in MDA-MB-231 tumor-bearing nude mice.

Notes: MDA-MB-231 cells were implanted in the nude mice on day 0, and the treatment was started on day 9 when the tumor volume reached ~100–200 mm3. The treatment involved the administration of 5% glucose solution as the control, Taxol (10 mg/kg), and NPPA-PTX@PEG NPs (12 mg/kg, equimolar to 10 mg/kg PTX) on days 9, 13, and 17, or a single administration of NPPA-PTX@PEG NPs (36 mg/kg, equimolar to 30 mg/kg PTX) on day 9. Data are presented as the mean ± SD per group measured on the indicated days after treatment (n=9). **P<0.01 compared to the control group; &&P<0.01 compared to the Taxol treatment group.

Abbreviations: NPPA, 3-(2-Nitrophenyl) propionic acid; NPPA-PTX@PEG NPs, NPPA-PTX nanoparticles prepared by NPPA-PTX and DSPE-PEG (NPPA-PTX:DSPE-PEG =1:0.1, w/w); PTX, paclitaxel.